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Purpose/Objective: 
Objective: Patients with locally recurrent rectal cancer have 
severe morbidity and poor quality of life. Most are ineligible 
for surgery, and combined re-irradiation and chemotherapy 
provides limited symptom palliation and tumor control [1]. 
Clinical data suggests that adding hyperthermia to radiation 
improves tumor response [2]. However, past studies used 
invasive temperature sensors that were poorly tolerated and 
provided insufficient thermal dosimetry. 
The objective of this study was to evaluate the feasibility in 
pigs of using MRI-HIFU to achieve mild hyperthermia in 
normal tissue targets that match typical locations for 
recurrent rectal cancer; and the quality of MR thermometry 
in consenting volunteers with biopsy-proven primary rectal 
cancer. 
Materials and Methods: 
Preclinical validation: 
The feasibility of MR-HIFU hyperthermia was evaluated in a 
swine model (N=6, study approved by the Local Animal Care 
Committee). Imaging and hyperthermia were performed using 
a clinical MRI (Achieva 3T, Philips Healthcare) with an 
integrated MR-HIFU system (Sonalleve, Philips Medical 
Systems). Different targets at thigh muscle (at the rectal wall 
and deep locations) were evaluated. Thermal maps were 
acquired in 6 slices along the beam were obtained every 3.2s. 
Sonications were prescribed with 18 mm diameter treatment 
regions at 1MHz with target temperature of 42-42.5°C, for 
10-60 min.  
Human imaging study  
The quality of MR thermometry of rectal cancers using MR-
HIFU was evaluated with an imaging-only study (no heating) 
including 6 consenting volunteers with rectal cancer. This 
study was approved by the Sunnybrook Research Ethics 
Board. Anatomical and MR thermometry images were 
acquired using the same MRI and MR-HIFU system and 
parameters as in the preclinical study. In 3/6 subjects, rectal 
filling with 200-300 mL of saline was used to reduce motion-
related artefacts in MR thermometry. Thermometry was 
performed in imaging slices located at the tumor. 
Results: Mean target temperature in the animal study 
matched the desired hyperthermia temperature to within 
0.2°C, varying temporally with a standard deviation of 0.5°C 
or lower. No evidence of tissue changes were observed on 
contrast-enhanced imaging or at necropsy. The imaging study 
with patients showed that MR-based temperature remained 
stable especially when rectal filling was used to reduce bowel 
motion. 
Figure 1. 
Figure 2. 
 
Conclusions: Our preclinical validation study demonstrated 
that MR-HIFU can safely deliver mild temperatures of 41 to 
43°C in a targeted volume for 30 minutes. Our clinical 
imaging study illustrates that with careful patient selection 
and preparation, the current MR-HIFU system may provide 
adequate treatment depth to target recurrent rectal cancers 
and sufficient MR temperature mapping stability for real-time 
control of mild hyperthermia exposures.  
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Purpose/Objective: Aim of this study is the evaluation of 
feasibility and efficacy of SBRT in the treatment of 
unresectable hepatocellular carcinoma (HCC). 
Materials and Methods: Patients with 1-3 inoperable HCC 
lesions with diameter ≤6cm were treated by SBRT. 
S350                                                                                                                                         3rd ESTRO Forum 2015 
 
Prescription dose was 36-75Gy in 3-6 fractions. SBRT was 
delivered using the volumetric modulated arc therapy 
technique with flattening filter free photon beams. The 
primary end points of this study were in–field local control 
(LC) and toxicity. Secondary end points were overall survival 
(OS) and progression free survival (PFS).  
Results: 43 patients with 63 HCC lesions were irradiated. All 
patients had Child-Turcotte-Pugh class A or B disease. Median 
follow-up was 8 months (range 3-43 months). Actuarial LC at 
1 and 2years was 86% and 64%. An Equivalent Dose >100Gy 
and GTV size were significant prognostic factors for LC in 
univariate analysis (p<0.001 and p<0.02). Median OS was 18 
months. Actuarial OS at 1 and 2 years was 78% and 45%, 
respectively. Univariate analysis showed that OS is correlated 
with LC (p<0.04), BED>100 (p<0.05) and Cumulative GTV<5cm 
(p<0.04). Median PFS was 8 months, with a 1-year PFS rate of 
41%. Grade ≥3 toxicity was observed in 7 patients (16%). No 
classic RILD was observed. 
Conclusions: Our study show that SBRT is a safe and effective 
treatment for selected patients with inoperable HCC. Local 
control rates and toxicity profile were encouraging.  
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Purpose/Objective: Chemoradiotherapy (CRT) followed by 
complete surgical removal is regarded as standard of care for 
locally advanced rectal cancer (LARC). To further improve 
clinical outcome therapeutic approaches may incorporate 
additional agents to the standard fluorouracil (FU)-based 
CRT. Intensified preoperative treatment with systemic 
neoadjuvant chemotherapy (NACT) before conventional long-
course CRT has shown promising long-term outcome and 
acceptable safety profiles. However, at present, it remains 
challenging to reliably identify good and poor responders at 
an early stage in order to achieve more individualized, 
effective and less toxic treatment of these patients. In this 
study, the purpose was to investigate if magnetic resonance 
imaging (MRI)-assessed tumor volumetry predicts histologic 
tumor response to NACT and subsequent CRT in LARC. 
Materials and Methods: The treatment in this experimental 
study consisted of two cycles of bolus 5-FU and oxaliplatin 
followed by long-course radiotherapy delivered 
concomitantly with capecitabine and oxaliplatin, before 
radical surgery. Complete MRI data sets and tumor 
histopathology from 69 prospectively enrolled patients were 
analyzed. Whole-tumor volumes were contoured in T2-
weighted MR images obtained pretreatment (VPRE), after 
NACT (VNACT), and after the full course of NACT followed by 
CRT (VCRT). VPRE, VNACT, and tumor volume changes relative to 
VPRE, DVNACT and DVCRT, were calculated and correlated to 
histologic tumor regression grade (TRG). 
Results: In total, 61% of good histologic responders (TRG 1-2) 
to NACT followed by CRT were correctly predicted by small 
pretreatment tumor volumes (VPRE < 10.5 cm3), large volume 
regressions after NACT (DVNACT > -78.2%), or small tumor 
volumes after NACT (VNACT < 3.3 cm3). Small pretreatment 
volume and large volume regression after NACT identified 
different patients; only six patients had both small 
pretreatment volume and large volume regression. Small 
tumor volume after NACT identified the majority of good 
responders (n = 27), with a sensitivity of 55.1% and a 
specificity of 100% (area under curve = 0.84), although the 
combined use of all three volumetric measurements 
identified the most. The volume regression after completed 
NACT and CRT (VCRT) was not significantly different between 
good and poor responders (TRG 1-2 versus TRG 3-5).  
Conclusions: MRI-assessed small tumor volumes following 
NACT, before the commencement of CRT, predicted good 
histologic tumor response (TRG1-2) to the completed course 
of NACT and CRT with high accuracy. Further, the combined 
use of tumor volume measurements before, during, and after 
NACT identified most good responders. MR volumetry may be 
used to improve individualized, multimodal treatment of 
LARC. 
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Purpose/Objective: To evaluate the role of 3T 
multiparametric MRI (3TmMRI) without endo-rectal coil (ERC) 
in the detection of radiographic local recurrences (rLR) in a 
contemporary cohort of patients with prostate cancer treated 
at our hospital and who presented a biochemical recurrence 
after PR with low PSA levels and to identify clinical 
parameters associated with the findings of the 3TmMRI.  
Materials and Methods: Between 2009 and 2013, 57 patients 
with biochemical recurrence after RP of a PC and considered 
for salvage radiation therapy (SRT) were included. 3TmMRI 
with T2-weighted imaging (T2WI), diffusion weighted imaging 
(DWI) and dynamic contrast-enhanced images (DCE) without 
ERC was carried out in all the patients prior to treatment. 
Given that there are no validated criteria, a points system 
was established to define the findings of the 3TmMRI, 0 being 
(normal; no abnormality was observed in the MRI sequences: 
T2WI, DWI or DCE), 1 being (doubtful; an abnormality was 
detected in one of the MRI sequences, with no correlation in 
the rest of the sequences) and 2 being (abnormal; 
abnormality detected in all or in two of the sequences). The 
local relapse was defined as 2. To analyze the relationship 
